AmerisourceBergen Corporation

source: coverage-next-full type: step_output step: 01 ticker: ABC company: Cencora, Inc. sector: Health Care generated: 2026-05-27

Step 01 — Business Overview: Cencora, Inc. (COR)

1. Company Summary

Cencora (formerly AmerisourceBergen) is the second-largest pharmaceutical distributor in the United States by revenue, and one of the largest healthcare services companies globally. Founded in 2001 from the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, the company rebranded to Cencora in August 2023 to better reflect its expanded, globally integrated identity [S1].

In FY2025 (fiscal year ended September 30, 2025), Cencora generated $321.3 billion in revenue, making it one of the largest companies in the world by revenue — roughly the GDP of a small-to-medium-sized nation. Yet its business is fundamentally one of logistics: moving pharmaceutical products through the supply chain as efficiently and reliably as possible, earning thin margins on massive volume.

The core business model: drug manufacturers produce medications and need to distribute them to the end points of care — pharmacies, hospitals, physician offices, clinics. Cencora sits as the intermediary, taking physical and economic ownership of drugs, warehousing them in temperature-controlled distribution centers, and delivering them rapidly and reliably. Manufacturers pay service fees (per-unit fees, data fees, logistics fees) and Cencora earns the spread between purchase price and sale price, with the spread driven largely by generic drug purchasing power and specialty distribution margins [S2].

2. Segment Structure

U.S. Healthcare Solutions (90.6% of FY2025 Revenue)

Revenue: $291.0B (FY2025), +9.7% YoY

The U.S. segment is divided into:

U.S. Human Health ($285.3B, +9.7%):

• Traditional pharmaceutical distribution to retail pharmacies (Walgreens is the largest customer), health systems, clinics, and specialty physician practices
• Specialty distribution (AmerisourceBergen Specialty Group / ABSG): Oncology, retina (post-RCA acquisition January 2025), neurology, rheumatology, dermatology — drugs dispensed directly in physician offices
• Manufacturer services: Clinical trial support, commercialization support, packaging, pharmacy management
• GLP-1 products: Became a dominant driver; +26.9% growth (+$7.7B) in FY2025 [S1]
• OneOncology (acquired February 2026): ~500+ physician practices, community oncology platform; adds further specialty depth

U.S. Animal Health ($5.7B, +6.1%):

• MWI Veterinary Supply: Distributes pharmaceuticals and products to companion animal and production animal markets
• Now classified as "Other" starting FY2026 as management explores strategic alternatives

Retina Consultants of America (RCA):

• Acquired January 2025 for ~$3.9B cash; ~85% Cencora ownership
• 200+ affiliated retina practices; largest retinal specialty practice network in U.S.
• Added significantly to FY2025 gross profit (+23% U.S. GP, driven by RCA)
• Classified within U.S. Human Health

International Healthcare Solutions (9.4% of FY2025 Revenue)

Revenue: $30.4B (FY2025), +6.1% YoY

Alliance Healthcare ($24.4B, +5.8%):

• Pan-European pharmaceutical distributor; acquired 2021 for ~$6.5B
• Operations in UK, Spain, Germany, Portugal, Turkey, and other European markets
• Standard pharmaceutical distribution with some retail pharmacy network
• Higher GP margin (~10-11%) than U.S. distribution business

Other International Healthcare Solutions ($6.0B, +7.3%):

• World Courier: Global specialty pharmaceutical logistics for clinical trials and biopharma
• PharmaLex: Regulatory affairs, pharmacovigilance, development consulting for life sciences (acquired January 2023; $1.4B; now subject to goodwill impairments — $418M FY2024, $724M FY2025)
• Innomar Strategies (Canada): Specialty pharmaceutical services
• Profarma (Brazil): Full-line pharmaceutical distribution (less-than-wholly-owned)

3. Value-Chain Position

MANUFACTURER → [Cencora] → HEALTHCARE PROVIDER → PATIENT
                    ↓
         Distribution Centers (~30 in U.S.)
         Temperature-controlled warehousing
         Track-and-trace serialization
         Credit and payment terms management
         Returns management

Cencora sits between ~1,500+ pharmaceutical manufacturers and ~100,000+ healthcare provider customers. This intermediary position generates several types of economic value:

1. Logistics efficiency: Manufacturers need not maintain direct-to-provider networks; Cencora's scale is irreplaceable
2. Working capital intermediary: Cencora extends credit to pharmacies and health systems, funded by supplier payment terms from manufacturers; the difference in DPO (60 days) vs. DSO (28 days) creates working capital float
3. Data and analytics: Purchase data from across the supply chain is monetized via manufacturer consulting and analytics services
4. Specialty access: In specialty segments, Cencora provides REMS program support, reimbursement services, and patient adherence tools that manufacturers cannot easily replicate

4. Revenue Model

5. Customer Concentration

• Top 2 customers represent ~37% + ~5% of accounts receivable (per FY2024 10-K) [S2]
• Walgreens Boots Alliance (WBA) is widely understood to be the largest customer
• Second-largest is likely Express Scripts / Evernorth (Cigna subsidiary); supply agreement extended through September 2029
• Healthcare system customers (hospital groups, IDNs) represent a growing and diversifying base
• GLP-1 pharmacy concentration: Significant sales to WBA and mail-order customers

6. Key Business Metrics (FY2025)

Source Index

source: coverage-next-full type: step_output step: 04 ticker: ABC company: Cencora, Inc. sector: Health Care generated: 2026-05-27

Step 04 — Financial Snapshot & Quality: Cencora, Inc. (COR)

1. Income Statement Analysis (5-Year)

Revenue & Profitability ($ millions, except per-share)

Note: FY2024 GAAP EPS suppressed by $418M goodwill impairment; FY2025 by $724M impairment. FY2025 adjusted EPS guidance: $17.65-$17.90 per company guidance (FY2026 raising implies FY2025 actual was in that range pre-raise).

Statement Quality Adjustments

1. LIFO Inventory Accounting: Cencora uses LIFO (last-in, first-out) for its U.S. pharmaceutical inventory. When drug prices inflate, LIFO creates an expense (LIFO expense) that reduces reported gross profit. When prices deflate (as in FY2024-FY2025 due to generic deflation and brand price decreases), LIFO creates a credit:

• FY2023: LIFO expense ($204.6M) — reduced gross profit
• FY2024: LIFO credit $52.2M — added to gross profit
• FY2025: LIFO credit $76.9M — added to gross profit

Adjustment: To compare periods, add back LIFO expense or subtract LIFO credit.

2. Antitrust Litigation Settlement Gains: Recurring gains from pharmaceutical manufacturer antitrust settlements (recorded as COGS reduction):

• FY2023: $239.1M
• FY2024: $170.9M
• FY2025: $236.4M

Adjustment: These are recurring but irregular; should be treated as below-the-line items.

3. Goodwill Impairments (PharmaLex):

• FY2024: $418M goodwill impairment (PharmaLex)
• FY2025: $724M goodwill impairment (PharmaLex + equity investment impairment $113.5M)

Adjustment: Remove from operating income; these reflect acquisition overpayment, not operating performance.

4. Opioid Litigation:

• FY2023: $24.7M credit (received H.D. Smith escrow)
• FY2024: $227.1M expense
• FY2025: $60.7M credit

Adjustment: Non-recurring in nature; exclude from adjusted earnings.

5. Turkey Hyperinflation:

• FY2023: ($87.0M) expense
• FY2024: ($54.1M) expense
• FY2025: ($49.6M) expense

Ongoing due to Turkish Lira devaluation; reflects the risk of Alliance Healthcare's Turkey operations.

6. Acquisition-Related Charges:

• FY2025: $291M deal & integration + $229M restructuring
• These are large and recurring as Cencora integrates Alliance Healthcare, PharmaLex, RCA, and OneOncology

Net Effect of Adjustments on Operating Income: When removing impairments, litigation, and other non-recurring items, "adjusted" segment operating income of $4.22B in FY2025 (vs. $2.63B GAAP) better represents underlying earning power.

2. Balance Sheet Analysis

Simplified Balance Sheet (September 30 estimates)

Note: Balance sheet estimates are based on XBRL data plus filing text. Significant debt increase in FY2025 due to $1.8B senior notes + $1.5B term loan for RCA; further increase Q2 FY2026 for OneOncology ($4.6B+ new financing).

Key observation: Cencora runs with near-negative equity when goodwill is stripped out (net tangible equity is negative). This is a feature of capital-light, high-velocity distribution businesses with massive trade payable leverage — NOT a sign of insolvency. The company's true capital position is reflected in its free cash flow generation.

3. Cash Flow Quality

Cash flow quality assessment: HIGH

• OCF consistently exceeds reported net income (2x+ coverage) due to non-cash charges (D&A, impairments) and working capital mechanics
• Very capital-light in the distribution business (CapEx is 0.2% of revenue — nearly negligible)
• FY2025 FCF of $3.2B funds dividends ($437M), buybacks ($436M), and still contributes to debt reduction/M&A funding
• Guidance for FY2026 CapEx = $900M (significant increase for network expansion + OneOncology integration)

4. Adversarial Research Sweep

4a. Opioid Litigation

Summary: Cencora was a central participant in the U.S. opioid epidemic litigation. As a major distributor of opioid medications, the company is alleged to have prioritized profit over flagging suspicious orders.

Settlement details:

• National settlement (joint with MCK and CAH): ~$21B over 18 years; Cencora's share approximately $6.1B over 18 years
• FY2025: Still 13 more years of opioid payments remaining
• Annual opioid payment run rate: ~$400-500M
• Director settlement: $111M separate settlement with shareholders alleging board oversight failure
• FY2025 litigation line: $60.7M net credit (timing of payments/settlements)

Risk assessment: Material but contained. The settlement is structured; Cencora's cash flows ($3.2B FCF) comfortably cover annual payments. The primary risk is additional litigation from remaining plaintiffs not covered by the national settlement.

4b. PharmaLex Acquisition Quality

Issue: Cencora acquired PharmaLex (regulatory consulting) in January 2023 for $1.4B. Within 18 months, it recorded $418M goodwill impairment (FY2024) and $724M impairment (FY2025) — together exceeding the acquisition price.

Analysis: This represents a clear acquisition failure. Management overpaid significantly for PharmaLex. The company is now exploring strategic alternatives for the consulting services businesses. This raises questions about M&A discipline, though it is worth noting that Alliance Healthcare (much larger acquisition) has performed well.

4c. Cybersecurity Incident (March 2024)

Issue: In March 2024, Cencora experienced a cybersecurity event where data was exfiltrated from its information systems. The incident was disclosed in the FY2024 10-K.

Impact: Costs recorded in "Other, net" within restructuring; amount not separately quantified but described as "majority of Other, net costs in FY2024." Likely a few tens of millions of dollars in remediation.

Risk: Ongoing. Cencora handles sensitive patient and pharmaceutical data; the 2024 breach increases the scrutiny of its cybersecurity posture. A follow-on incident could be more costly.

4d. WBA Customer Concentration Risk

Issue: Walgreens Boots Alliance (WBA) is Cencora's largest customer. WBA has been facing serious financial difficulties — pharmacy reimbursement rate pressure, retail store losses, and ongoing restructuring. WBA has been closing stores and may reduce purchasing volumes.

Impact: WBA represents ~37% of Cencora's top-2 accounts receivable. Any significant reduction in WBA purchases would be material to Cencora's revenue.

Mitigating factors: Long-term supply agreement through 2029; Cencora cannot easily be replaced as WBA's distributor; WBA has contracted to purchase minimums.

4e. OneOncology Acquisition Risk (Feb 2026)

Issue: Cencora acquired the remaining ~92% of OneOncology in February 2026 for ~$4.6B cash + $752M contingent consideration + assumed equity. Total fair value ~$7.4B. This is on top of RCA ($3.9B, Jan 2025). Combined, these two deals added ~$8B+ of cash outflow in 13 months, funded largely by new debt.

Analysis: The speed and scale of M&A is aggressive. PharmaLex failure is precedent for risk. However, OneOncology's community oncology model has a clearer strategic rationale — it directly drives specialty pharmaceutical volume at independent oncology practices that are Cencora's natural distribution customers. The key risk is integration execution and debt service burden.

5. Financial Quality Summary

Overall Financial Quality: MODERATE-HIGH (3.5/5)

Cash flow generation is excellent; the balance sheet is structurally leveraged (by design for a distribution company); GAAP earnings are heavily distorted by recurring non-cash items. Investors must focus on adjusted earnings and FCF.

Source Index